Reata Pharmaceuticals Submits MAA to the EMA for Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals MAA Submission for Bardoxolone Methyl
Reata Pharmaceuticals (RETA) announced the submission of a Marketing Authorization Application (MAA) for bardoxolone methyl to the European Medicines Agency (EMA) for chronic kidney disease (CKD) caused by Alport syndrome.

The MAA submission is based on the efficacy and safety data from the CARDINAL Phase 3 clinical trial. This . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.